Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer

Aaron M. Allen; Mohamed Elshaikh; Francis P. Worden; Carol R. Bradford; Theodores N. Teknos; Douglas B. Chepeha; Christina Tsien; Laura A. Dawson; Susan Urba; Gregory T. Wolf; Daniel Normolle; Avraham Eisbruch

doi:10.1002/hed.20495

Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer

Aaron M. Allen, Mohamed Elshaikh, Francis P. Worden, Carol R. Bradford, Theodores N. Teknos, Douglas B. Chepeha, Christina Tsien, Laura A. Dawson, Susan Urba, Gregory T. Wolf, Daniel Normolle, Avraham Eisbruch

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m²/day and 5-fluorouracil 600 mg/m²/day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. Results. Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was -3.8% and -7.9%, respectively (p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. Conclusions. In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients.

Original language	English (US)
Pages (from-to)	137-142
Number of pages	6
Journal	Head and Neck
Volume	29
Issue number	2
DOIs	https://doi.org/10.1002/hed.20495
State	Published - Feb 2007
Externally published	Yes

Keywords

Altered fractionation
Chemotherapy
Dysphagia
Head and neck cancer
Radiotherapy

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.20495

Cite this

@article{70f93f876a76499ba0f7c9880e410af3,

title = "Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer",

abstract = "Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m2/day and 5-fluorouracil 600 mg/m2/day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. Results. Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was -3.8% and -7.9%, respectively (p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. Conclusions. In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients.",

keywords = "Altered fractionation, Chemotherapy, Dysphagia, Head and neck cancer, Radiotherapy",

author = "Allen, {Aaron M.} and Mohamed Elshaikh and Worden, {Francis P.} and Bradford, {Carol R.} and Teknos, {Theodores N.} and Chepeha, {Douglas B.} and Christina Tsien and Dawson, {Laura A.} and Susan Urba and Wolf, {Gregory T.} and Daniel Normolle and Avraham Eisbruch",

year = "2007",

month = feb,

doi = "10.1002/hed.20495",

language = "English (US)",

volume = "29",

pages = "137--142",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer

AU - Allen, Aaron M.

AU - Elshaikh, Mohamed

AU - Worden, Francis P.

AU - Bradford, Carol R.

AU - Teknos, Theodores N.

AU - Chepeha, Douglas B.

AU - Tsien, Christina

AU - Dawson, Laura A.

AU - Urba, Susan

AU - Wolf, Gregory T.

AU - Normolle, Daniel

AU - Eisbruch, Avraham

PY - 2007/2

Y1 - 2007/2

N2 - Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m2/day and 5-fluorouracil 600 mg/m2/day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. Results. Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was -3.8% and -7.9%, respectively (p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. Conclusions. In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients.

AB - Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regimen: 1.25 Gy twice daily to 70 Gy concurrent with cisplatin 12 mg/m2/day and 5-fluorouracil 600 mg/m2/day for 5 days, weeks 1, 5. This regimen was accelerated in this series by shortening the treatment from 7 to 6 weeks by omitting the planned mid-treatment 1-week break. Results. Forty-six patients with T3-4/N3 disease were treated. The main acute toxicity was pharyngeal. Median weight change during therapy in patients with and without enteral feeding tubes was -3.8% and -7.9%, respectively (p = .08). Fifteen percent had late grade III pharyngeal toxicity. Local/regional and distant failure rates were 28% and 17%, respectively; 52% are alive without evidence of disease. Conclusions. In nonresectable HNSCC, acceleration of the HxCRT regimen is feasible, requiring enteral feeding tubes during therapy in most patients.

KW - Altered fractionation

KW - Chemotherapy

KW - Dysphagia

KW - Head and neck cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33846543074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846543074&partnerID=8YFLogxK

U2 - 10.1002/hed.20495

DO - 10.1002/hed.20495

M3 - Article

C2 - 17111432

AN - SCOPUS:33846543074

SN - 1043-3074

VL - 29

SP - 137

EP - 142

JO - Head and Neck

JF - Head and Neck

IS - 2

ER -

Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this